Literature DB >> 12927521

Specificity of antibodies directed against the cytolethal distending toxin of Haemophilus ducreyi in patients with chancroid.

Judica Mbwana1, Hinda J Ahmed, Karin Ahlman, Vivian Sundaeus, Gunnar Dahlén, Eligius Lyamuya, Teresa Lagergård.   

Abstract

Antibodies specific for the cytolethal-distending toxin of Haemophilus ducreyi (HdCDT) complex and for the CdtA, CdtB, and CdtC components were measured by ELISA in the sera of 50 patients with culture and/or PCR proven chancroid, 42 patients with periodontitis, 50 blood donors from Tanzania, 50 blood donors from Sweden. In addition, the biological activity e.g. neutralization capacity of the sera were tested. Our results demonstrate that majority of chancroid patients and healthy individuals had detectable levels of serum antibodies to HdCDT complex and to separate toxin components. However, high levels (> or =100 units) of antibodies to HdCDT complex were significantly more prevalent in the sera of patients with both chancroid and periodontitis than in the sera of the corresponding controls (P=0.001 and P=0.04, respectively). In the sera of the 50 patients with chancroid, antibodies to CdtA, CdtB, and CdtC were detected in 50, 35, and 34 individuals, respectively. Antibodies to CdtC, being less frequently detected than the antibodies to other components, show a good correlation with the neutralizing capacity of sera. High levels of neutralizing antibodies (> or =160) were detected in only 22 and 2% of the patients with chancroid and periodontitis, respectively. The data suggest that the low levels of anti-HdCDT antibodies, which include neutralizing antibodies, may contribute to limited protection in chancroid and since anti-HdCDT antibodies, may be detected in healthy individuals and in patients with certain disease conditions (e.g. periodontitis), they may not be specific markers for chancroid infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927521     DOI: 10.1016/s0882-4010(03)00111-6

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  6 in total

1.  Immune response to cytolethal distending toxin of Aggregatibacter actinomycetemcomitans in periodontitis patients.

Authors:  E S Ando; L A De-Gennaro; M Faveri; M Feres; J M DiRienzo; M P A Mayer
Journal:  J Periodontal Res       Date:  2010-03-09       Impact factor: 4.419

2.  The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells.

Authors:  G N Belibasakis; A Johansson; Y Wang; C Chen; S Kalfas; U H Lerner
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  Cytolethal distending toxin: a conserved bacterial genotoxin that blocks cell cycle progression, leading to apoptosis of a broad range of mammalian cell lineages.

Authors:  Rasika N Jinadasa; Stephen E Bloom; Robert S Weiss; Gerald E Duhamel
Journal:  Microbiology (Reading)       Date:  2011-05-12       Impact factor: 2.777

4.  Evaluation of the humoral immune response to the cytolethal distending toxin of Aggregatibacter actinomycetemcomitans Y4 in subjects with localized aggressive periodontitis.

Authors:  I Xynogala; A Volgina; J M DiRienzo; J Korostoff
Journal:  Oral Microbiol Immunol       Date:  2009-04

5.  Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study.

Authors:  Maryam Keshtvarz; Mahdieh Mahboobi; Marek Kieliszek; Antoni Miecznikowski; Hamid Sedighian; Milad Rezaei; Mohammad Ali Haghighi; Zahra Zareh; Ehsan Rezaei
Journal:  Toxins (Basel)       Date:  2021-11-05       Impact factor: 4.546

Review 6.  Impact of CDT Toxin on Human Diseases.

Authors:  Tiphanie Faïs; Julien Delmas; Arnaud Serres; Richard Bonnet; Guillaume Dalmasso
Journal:  Toxins (Basel)       Date:  2016-07-15       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.